

**IMEXPHARM CORPORATION****THE SOCIALIST REPUBLIC OF VIETNAM****Independence - Freedom - Happiness**No.: *02* /2025/TTr-HĐQT-IMP

Cao Lanh City, April 03, 2025

PROPOSAL***Re.: Approval of the audited 2024 Financial Statements*****Kindly Attn: Esteemed Shareholders of Imexpharm Corporation**

- Pursuant to the Law on Enterprises;
- Pursuant to the Charter of Imexpharm Corporation (the "Company");
- Based on the 2024 audited Financial statements prepared by KPMG Limited's Branch in Ho Chi Minh City (Vietnam) dated March 18, 2025.

The Board of Directors ("BOD") respectfully submits to the 2025 Annual General Meeting of Shareholders ("AGM") for approval of the 2024 Financial statements of Imexpharm Corporation which has been audited by KPMG Limited's Branch in Ho Chi Minh City (Vietnam) as follows:


The audited 2024 financial statements have been disclosed in accordance with regulations on the Company's website, including:

1. Company's profile;
2. Statement of the Board of Management;
3. Independent Auditor's Report;
4. Balance sheet (Form No. B01-DN);
5. Income Statement (Form No. B02-DN);
6. Cash Flow Statement (Form No. B03-DN);
7. Notes to the Financial Statements (Form No. B09-DN).

In which:

Some basic indicators in the audited 2024 Financial statements:

No.	Major indicators	Unit	2024	2023
1	Total assets	VND	2,504,776,666,933	2,392,615,157,119
2	Gross revenue	VND	2,512,786,046,784	2,113,869,795,523
3	Net revenue	VND	2,205,119,938,413	1,994,036,910,377
4	Profit before tax	VND	404,192,934,555	377,272,934,101
5	Profit after tax	VND	320,862,393,082	299,556,005,542





IMEXPHARM
Initially Being Committed


TOP QUALITY - EUROPEAN STANDARD

Respectfully submitting to the AGM for consideration and approval.

nh

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRPERSON



SUNG MIN WOO

